Abiopharma

Wells Fargo Named as ICON Preferred Mortgage Lender to Support 3D‑Printed Homes

Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel

Wiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain

Principal Asset Management® Launches Fixed Income ETF Suite

Cuprina Receives U.S. FDA 510(k) Clearance for MEDIFLY Maggots — the First U.S. Clearance for a Lucilia cuprina Maggot Debridement Product

JPMorganChase Expands Security and Resiliency Initiative to Canada

Wix Partners with Microsoft 365 Copilot to Bring Website Creation into the Flow of Work

CETY Partnership With Sagacity Yields Success in Design and Manufacture of Advanced ORC Components, Significantly Reducing System Costs and Strengthening Supply Chain Efficiency

XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis

XBiotech lance un essai clinique de phase II visant à évaluer le vilamakitug dans le traitement de la spondylarthrite axiale active